SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Solomon S. D.)
 

Sökning: WFRF:(Solomon S. D.) > (2010-2014) > Efficacy and safety...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003376naa a2200445 4500
001oai:gup.ub.gu.se/124927
003SwePub
008240528s2010 | |||||||||||000 ||eng|
0247 a https://gup.ub.gu.se/publication/1249272 URI
040 a (SwePub)gu
041 a eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Chang, S. M.4 aut
2451 0a Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme
264 1c 2010
520 a AIMS: It is unknown whether there is an interaction between aspirin and angiotensin receptor blockers on outcomes in patients with heart failure (HF). METHODS AND RESULTS: The efficacy and safety of candesartan vs. placebo was assessed in 7599 patients with symptomatic HF and reduced or preserved left ventricular ejection fraction enrolled in the CHARM programme according to baseline aspirin use. Patients were randomized to candesartan or matching placebo and were followed for a median of 38 months. Aspirin was used in 4246 (55.9%) of patients at baseline. When compared with placebo, candesartan use was associated with lower event rates for cardiovascular (CV) death or HF hospitalization (primary outcome) in both the aspirin group (28 vs. 31.9%, HR 0.81, 95% CI 0.72-0.90) and non-aspirin group (33 vs. 38%, HR 0.81, 95% CI 0.72-0.91). Baseline aspirin use did not modify the effectiveness of candesartan in reducing the risk of CV death or HF hospitalization in CHARM overall (P = 0.64) or in the CHARM individual trials. In addition, there was no significant interaction between aspirin therapy and candesartan in terms of discontinuation of study drug due to adverse reactions (P = 0.72). CONCLUSION: There appears to be no significant modification of the benefit of candesartan on CV mortality and morbidity outcomes or safety by concomitant use of aspirin in patients with chronic HF.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kardiologi0 (SwePub)302062 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cardiac and Cardiovascular Systems0 (SwePub)302062 hsv//eng
653 a Heart failure
653 a Candesartan
653 a Receptor
653 a Angiotensin
653 a Antiplatelet therapy
7001 a Granger, C. B.4 aut
7001 a Johansson, P. A.4 aut
7001 a Kosolcharoen, P.4 aut
7001 a McMurray, J. J.4 aut
7001 a Michelson, E. L.4 aut
7001 a Murray, D. R.4 aut
7001 a Olofsson, B.4 aut
7001 a Pfeffer, M. A.4 aut
7001 a Solomon, S. D.4 aut
7001 a Swedberg, Karl,d 1944u Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin,Institute of Medicine, Department of Emergeny and Cardiovascular Medicine4 aut0 (Swepub:gu)xsweka
7001 a Yusuf, S.4 aut
7001 a Dunlap, M. E.4 aut
7102 a Göteborgs universitetb Institutionen för medicin, avdelningen för akut och kardiovaskulär medicin4 org
7730 t European Journal of Heart Failureg 12:7, s. 738-745q 12:7<738-745x 1388-9842
8564 8u https://gup.ub.gu.se/publication/124927

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy